Molecular Partners AG, a leader in the development of next generation therapeutics, announced today that it has completed two phase I/IIa clinical trials with MP0112, its lead molecule targeting VEGF-A.
Author: The Medical News
Too much TV raises risk of narrow eye blood vessels and heart disease in kids
A new study has shown that children who spend more time in front of television and computer screens and less in outdoor physical activity have narrower blood vessels in their eyes. In adults, constricted blood vessels in the eyes have been linked to an…
Humana declares quarterly cash dividend, anticipates first quarter diluted EPS of $1.86
Humana Inc. announced today that it has realigned its business segments to more closely reflect the company’s evolving business model. Effective immediately, the company will be managing and reporting its operating results using the following segments:…
Researchers report game-changing advance in stem cell science
In a paper published in the April 25 early online edition of the Proceedings of the National Academy of Sciences, researchers at the University of California, San Diego School of Medicine, the Gladstone Institutes in San Francisco and colleagues report…
Bioengineering students develop new device that can detect patients with dry eye
Rice University bioengineering students responded to an ophthalmologist’s cry for help with a device to diagnose dry eye, the itching and burning sensation that results when a person doesn’t produce enough tears or the tears evaporate too quickly.
STAA receives CE Mark approval for Visian Implantable Collamer Lens V4 design
STAAR Surgical Company, the leading developer, manufacturer and marketer of minimally invasive ophthalmic lenses for refractive surgery, today announced CE Mark approval for its Visian Implantable Collamer Lens V4c design.
Promedior to present PRM-151 study data in age-related macular degeneration at ARVO meeting
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of PRM-151 will be presented at the Annual Meeting of the As…
WSU researcher develops potential vaccine for Chlamydia
A Wayne State University School of Medicine researcher has developed a potential first ever vaccine for Chlamydia, the world’s most prevalent sexually transmitted disease and the leading cause of new cases of blindness.
Researchers create artificial cornea using pig and human stem cells
Researchers extracted pig corneal cells and replaced them with human stem cells. Thus, the University of Granada takes the lead in the making of bioartificial organs, a field so far led by the Hospital Gregorio Marañón in Madrid.
Women older than 75 with high vitamin D status less likely to have early AMD
Women under the age of 75 with high vitamin D status were less likely to have early age-related macular degeneration, the leading cause of irreversible vision loss in adults, a University at Buffalo study has shown. The disease affects approximately 9 …
Long-term delivery of CNTF slows loss of visual acuity caused by geographic atrophy
A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression of vision loss for this disease. The resu…
A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury
Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.
Neurotech’s NT-501 intraocular implant slows progression of vision loss in GA subjects
Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dr…
Merck enters definitive agreement to acquire Inspire
Merck, known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on develop…
New Mexico Software annual revenue decreases 5% to $3.48 million
New Mexico Software, Inc. announced today its financial results, reporting annual revenue in 2010 decreased approximately 5% to $3.48 million compared to $3.66 million in 2009.
Omeros announces outcome from OMS103HP Phase 3 study in patients undergoing ACL surgery
Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today reported the outcome from its Phase 3 program evaluat…
IOVS journal publishes first global consensus report on MGD
The first global consensus report on meibomian gland dysfunction – a major cause of lid disease and evaporative dry eye – has been published in a special issue of the Investigative Ophthalmology & Visual Science journal.
Surgeon presents LASIK procedure comparative study results at ASCRS Symposium
LasikPlus surgeon Dr. Lewis Groden presented results from a first-of-its-kind, comparative study at the American Society of Cataract and Refractive Surgery Symposium revealing that LASIK procedures performed with modern excimer laser technology produce…
Stanford professor receives AFER Ludwig von Sallman Clinician-scientist Award
Karl Deisseroth, MD, PhD, has been named the first recipient of the Ludwig von Sallman Clinician-scientist Award, presented by the ARVO Foundation for Eye Research to a clinician-scientist under age 40.
Abbott launches Cataract Suite for micro-implantation procedure
Abbott announced today that it has introduced a Micro-Implantation Cataract Suite designed to help improve cataract procedure outcomes and safety.